Compare CLST & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLST | ENTX |
|---|---|---|
| Founded | 1922 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.8M | 74.7M |
| IPO Year | 2021 | 2015 |
| Metric | CLST | ENTX |
|---|---|---|
| Price | $16.73 | $1.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 3.8K | ★ 176.1K |
| Earning Date | 04-30-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.43 | 0.18 |
| Revenue | N/A | ★ $181,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $38.91 | ★ $7.75 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.67 | $1.00 |
| 52 Week High | $16.98 | $3.22 |
| Indicator | CLST | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 68.57 | 44.23 |
| Support Level | $12.12 | $1.00 |
| Resistance Level | N/A | $2.28 |
| Average True Range (ATR) | 0.29 | 0.12 |
| MACD | 0.07 | 0.01 |
| Stochastic Oscillator | 81.75 | 12.90 |
Catalyst Bancorp Inc is a bank holding company. Through its subsidiary, which is a federally chartered community-oriented savings bank, it is engaged in attracting deposits from the general public and using those funds to invest in loans and securities. The sources of funds are customer deposits, repayments of loans, maturities of investments, and funds borrowed from outside sources, which are used for the origination of loans. It derives income principally from interest earned on loans and investment securities and, to a lesser extent, from fees received in connection with the origination of loans, service charges on deposit accounts, and other services.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.